• Skip to primary navigation
  • Skip to main content
高瓴 Hillhouse

高瓴 Hillhouse

Hillhouse builds businesses that stand the test of time

  • 关于我们
    • 高瓴的专业团队
    • 高瓴的投资策略
    • 高瓴与公益事业
  • 新闻报道
  • 英语

Updates

祝贺Akero上市,高瓴一周内迎来两家被投企业IPO

Posted in 新闻报道 on

美国东部时间6月20日上午,高瓴投资的生物制药公司Akero Therapeutics正式在美国纳斯达克上市。此前,翰森制药于6月14日成功登陆港股,一周之内,高瓴喜迎两家医药类被投企业上市。

Akero Therapeutics股票代码为“AKRO”, 拟定发行价区间为每股14-16美元,最终发行价为每股16美元,达到发行价区间上限,发行份额由原定的500万股增至575万股,上市首日大涨14.5%,股价报收18.32美元。

Akero Therapeutics位于美国旧金山,是一家临床阶段的生物技术公司,致力于为严重代谢疾病患者提供治疗选择,其中,非酒精性脂肪性肝炎(NASH)是其正在努力的重要方向。NASH是一种肝脏炎症或肝细胞损伤导致肝纤维化、肝硬化、肝功能衰竭乃至死亡的疾病。Akero的首款候选药物AKR-001是一款新型长效成纤维细胞生长因子21(FGF21)的类似物,被认为是潜在的NASH最佳治疗药物。研究表明,内源激素FGF21在人体代谢和信号调节中发挥着关键作用,其能够作用于包括肝脏在内的多种器官系统。据悉,该款药物与天然FGF21相比,能够显著提高稳定性和半衰期,增强与受体的结合和活性。

根据Hepatology(2018)发表的一项研究,预计到2030年,美国NASH患者人数将从2016年的1730万增加到2700万,特别是美国晚期纤维化患者的人数预计将增加一倍以上。可以预见,该领域未来将会产生更大规模的医疗需求。

秉持着长期价值投资理念,一直以来,高瓴都将生物医药和医疗健康行业作为重点投资领域,深入研究和理解行业动态,支持了一大批国内外优秀医疗、医药企业的发展,致力于做创新药研发企业的长期投资人,除Akero以外,还投资了百济神州、药明康德、君实生物、信达生物、甘李药业等国内外很多优秀的医药企业。作为Akero的重要投资人,今后高瓴将继续与Akero携手并进,支持Akero加快医药研发和创新步伐,惠及更多患者,创造长期价值。

Filed Under: 新闻报道

Copyright © 2022 Hillhouse • Terms of Use

  • LinkedIn
  • Instagram
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Cookie settingsACCEPT
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT